{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:52:16Z","timestamp":1790031136761,"version":"4.0.1"},"reference-count":34,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2016,2,26]],"date-time":"2016-02-26T00:00:00Z","timestamp":1456444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2016,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            ABT-493 is a hepatitis C virus (HCV) nonstructural (NS) protein 3\/4A protease inhibitor, and ABT-530 is an HCV NS5A inhibitor. These direct-acting antivirals (DAAs) demonstrated potent antiviral activity against major HCV genotypes and high barriers to resistance\n            <jats:italic>in vitro<\/jats:italic>\n            . In this open-label dose-ranging trial, antiviral activity and safety were assessed during 3 days of monotherapy with ABT-493 or ABT-530 in treatment-naive adults with HCV genotype 1 infection, with or without compensated cirrhosis. The presence of baseline resistance-associated variants (RAVs) was also evaluated. The mean maximal decreases in HCV RNA levels from baseline were approximately 4 log\n            <jats:sub>10<\/jats:sub>\n            IU\/ml for all ABT-493 doses ranging from 100 mg to 700 mg and for ABT-530 doses of \u226540 mg. There were no meaningful differences in viral load declines for patients with versus without compensated cirrhosis. Twenty-four (50%) of the baseline samples from patients treated with ABT-493 had RAVs to NS3\/4A protease inhibitors. Among 40 patients treated with ABT-530, 6 (15%) carried baseline RAVs to NS5A inhibitors. Viral load declines in patients with single baseline NS5A RAVs were similar to those in patients without RAVs. One patient harbored baseline RAVs at 3 NS5A positions and appeared to have a slightly less robust viral load decline on day 3 of monotherapy. No serious or grade 3 (severe) or higher adverse events and no clinically relevant laboratory abnormalities were observed with either compound. ABT-493 and ABT-530 demonstrated potent antiviral activity and acceptable safety during 3-day monotherapy in patients with HCV genotype 1 infection, with or without compensated cirrhosis. Based on these results, phase II studies assessing the combination of these DAAs for the treatment of chronic HCV infection in patients with or without compensated cirrhosis have been initiated. (This study has been registered at ClinicalTrials.gov under registration no. NCT01995071.)\n          <\/jats:p>","DOI":"10.1128\/aac.02264-15","type":"journal-article","created":{"date-parts":[[2015,12,29]],"date-time":"2015-12-29T03:23:15Z","timestamp":1451359395000},"page":"1546-1555","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":48,"title":["Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection"],"prefix":"10.1128","volume":"60","author":[{"given":"Eric J.","family":"Lawitz","sequence":"first","affiliation":[{"name":"Texas Liver Institute, University of Texas Health Science Center, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"O'Riordan","sequence":"additional","affiliation":[{"name":"eStudySite, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armen","family":"Asatryan","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley L.","family":"Freilich","sequence":"additional","affiliation":[{"name":"Kansas City Gastroenterology &amp; Hepatology, Kansas City, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry D.","family":"Box","sequence":"additional","affiliation":[{"name":"Clinical Research Centers of America, Murray, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Scott","family":"Overcash","sequence":"additional","affiliation":[{"name":"eStudySite, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Lovell","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa I.","family":"Ng","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Campbell","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Wei","family":"Lin","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty","family":"Yao","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kort","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26141"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.11.003"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.03.004"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.12.028"},{"key":"e_1_3_2_6_2","volume-title":"Sovaldi (sofosbuvir): prescribing information","author":"Gilead Sciences","year":"2014","unstructured":"Gilead Sciences. 2014. Sovaldi (sofosbuvir): prescribing information. Gilead Sciences, Foster City, CA."},{"key":"e_1_3_2_7_2","volume-title":"Abstr 21st Annu Conf Retroviruses Opportunistic Infect","author":"Ng T","year":"2014","unstructured":"Ng T, Krishnan P, Kati W, Reisch T, Lu L, Dekhtyar T, Molla A, Collins C, Pilot-Matias T. 2014. ABT-530, an HCV NS5A inhibitor with potent pangenotypic activity and high genetic barrier to resistance. Abstr 21st Annu Conf Retroviruses Opportunistic Infect, abstr 639."},{"key":"e_1_3_2_8_2","volume-title":"Abstr 21st Annu Conf Retroviruses Opportunistic Infect","author":"Ng T","year":"2014","unstructured":"Ng T, Reisch T, Middleton T, McDaniel K, Kempf D, Lu L, Wang G, Jiang L, Or YS, Pilot-Matias T. 2014. ABT-493, a potent HCV NS3\/4A protease inhibitor with broad genotypic coverage. Abstr 21st Annu Conf Retroviruses Opportunistic Infect, abstr 636."},{"key":"e_1_3_2_9_2","first-page":"1142A","article-title":"A next generation HCV DAA combination: potent, pangenotypic inhibitors ABT-493 and ABT-530 with high barriers to resistance","volume":"60","author":"Ng T","year":"2014","unstructured":"Ng T, Pilot-Matias T, Liangjun L, Reisch T, Dekhtyar T, Krishnan P, Beyer J, Tripathi R, Pithawalla RB, Asatryan A, Campbell AL, Kort J, Collins C. 2014. A next generation HCV DAA combination: potent, pangenotypic inhibitors ABT-493 and ABT-530 with high barriers to resistance. Hepatology 60:1142A.","journal-title":"Hepatology"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(90)90001-N"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01320-07"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04227-14"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04226-14"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27934"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(14)61390-8"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02193-12"},{"key":"e_1_3_2_17_2","unstructured":"National Cancer Institute. 2009. Common terminology criteria for adverse events (CTCAE) version 4.03. National Institutes of Health Bethesda MD. http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.10.033"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.07.117"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00780-12"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2415"},{"key":"e_1_3_2_22_2","first-page":"176","article-title":"Antiviral activity of GS-9451, an HCV specific NS3 protease inhibitor, in a three-day, dose-ranging, monotherapy study in patients with genotype 1 hepatitis C infection","volume":"6","author":"Yang J","year":"2012","unstructured":"Yang J, Hongmei H, Dvory-Sobol H, Lawitz EJ, Moorehead L, Mathias A, Delaney W, McHutchinson J. 2012. Antiviral activity of GS-9451, an HCV specific NS3 protease inhibitor, in a three-day, dose-ranging, monotherapy study in patients with genotype 1 hepatitis C infection. Hepatol Int 6:176.","journal-title":"Hepatol Int"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.01.041"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.02.037"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2014.902049"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)31104-1"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.12.029"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24609"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)61198-2"},{"key":"e_1_3_2_30_2","first-page":"433A","article-title":"Deep sequencing of HCV NS5A from a 3-day study of GS-5816 monotherapy confirms the potency of GS-5816 against pre-existing genotype 1\u20133 NS5A resistance-associated variants","volume":"58","author":"Hebner C","year":"2013","unstructured":"Hebner C, Gontcharova V, Chodavarapu RK, Rodriguez-Torres M, Lawitz EJ, Yang C, McNally J, Link JO, Mo H. 2013. Deep sequencing of HCV NS5A from a 3-day study of GS-5816 monotherapy confirms the potency of GS-5816 against pre-existing genotype 1\u20133 NS5A resistance-associated variants. Hepatology 58:433A\u2013434A.","journal-title":"Hepatology"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(13)61061-2"},{"key":"e_1_3_2_32_2","first-page":"438A","article-title":"MK-8742, a HCV NS5A inhibitor with a broad spectrum of HCV genotypic activity, demonstrates potent antiviral activity in genotype-1 and -3 HCV-infected patients","volume":"58","author":"Yeh WW","year":"2013","unstructured":"Yeh WW, Lipardi C, Jumes P, De Lepeleire IM, Van den Bulk N, Caro L, Huang X, Mangin E, Nachbar RB, Gane EJ, Popa S, Ghicavii N, Wagner FD, Butterton JR. 2013. MK-8742, a HCV NS5A inhibitor with a broad spectrum of HCV genotypic activity, demonstrates potent antiviral activity in genotype-1 and -3 HCV-infected patients. Hepatology 58:438A\u2013439A.","journal-title":"Hepatology"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)31101-6"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12435"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(13)60878-8"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02264-15","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02264-15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:39:43Z","timestamp":1645475983000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02264-15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.1128\/AAC.02264-15"],"URL":"https:\/\/doi.org\/10.1128\/aac.02264-15","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"2015-09-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-12-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-02-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}